Randomized Trialhigh evidence
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.
JAMA·June 7, 2026·PMID 42251595
Why it mattersMazdutide is a novel dual glucagon/GLP-1 receptor agonist that produced substantial weight loss in a Chinese population with obesity. This adds to the growing armamentarium of incretin-based therapies and may offer an alternative for patients who do not tolerate or respond to existing agents.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled